Clinical trials: asthma
Asthma
MGR001 / Advair Diskus Local Equivalence Study in Asthma
The purpose of this study is to determine whether MGR001 is equivalent to Advair Diskus when administered by inhalation in adult asthma patients
- Trial name
- NCT02245672
- Testing
- MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
- Where
- 101 sites in United States
- Volunteers
- 1,128 people
- Sponsor
- Mylan Pharma UK Ltd.
Asthma
Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma
The aim of this study is to evaluate the expression of IgE high affinity receptors (the part of the cell associated with allergic response) in patients suffering from uncontrolled severe asthma despite long term treatment with…
- Trial name
- NCT00454051
- Testing
- Omalizumab
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Feasibility Trial of a Mobile Adherence Tool for Adolescents With Asthma
The purpose of this study is to assess the feasibility of using a mobile health intervention to improve adherence to asthma medication among adolescents in an urban clinic setting.
- Trial name
- NCT02426801
- Testing
- Inhaler sensor, Mobile application for asthma adherence
- Volunteers
- 16 people
- Sponsor
- CoheroHealth
Severe Eosinophilic Asthma
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
- Trial name
- ATHENA (NCT07214753)
- Testing
- benralizumab
- Where
- 28 sites in Italy
- Volunteers
- 335 people
- Sponsor
- AstraZeneca
Allergic Asthma, Atopic Dermatitis
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1 study to evaluate the safety of MEDI4212.
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Trial name
- NCT01544348
- Testing
- Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous
- Where
- 7 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Bronchial Asthma
Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)
The aim of this study was to compare the efficacy and tolerability of the fixed combination beclomethasone/formoterol pMDI with that of budesonide/formoterol dry powder via Turbuhaler.
- Trial name
- NCT00413387
- Testing
- beclomethasone dipropionate plus formoterol fumarate combination, budesonide plus formoterol combination
- Where
- 13 sites in Austria, Poland and 1 more
- Volunteers
- 219 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, Healthy Volunteers
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729
RV1729 is a new medicine being developed for possible treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT01813084
- Testing
- RV1729 single dose, RV1729: 14 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Asthma
To Test The Relative Bioavailability Of PF-04191834 When Dosed As An Immediate Release Tablet Compared With Solution Following Single And Multiple Dosing
To test the relative bioavailability of PF-04191834 when dosed as an Immediate Release tablet compared with solution following single and multiple dosing.
- Trial name
- NCT01064804
- Testing
- PF-04191834
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma
Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)
a study to describe patient and physician satisfaction with montelukast therapy for the control of asthma used either as monotherapy or in combination with inhaled corticosteroids
- Trial name
- NCT00832455
- Testing
- montelukast sodium
- Volunteers
- 445 people
- Sponsor
- Organon and Co
Asthma
Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy
The purpose of this study is to determine whether patients with asthma are better able to manage and control their symptoms by using one inhaler daily that both prevents as well as treats the symptoms of an asthma exacerbation.
- Trial name
- RELEASE (NCT00319306)
- Testing
- Budesonide/formoterol, Symbicort® Turbohaler®
- Where
- 59 sites in United Kingdom
- Volunteers
- 550 people
- Sponsor
- AstraZeneca
Asthma
Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma
This clinical study was designed to assess the pharmacokinetics, safety and tolerability of single inhaled doses of mometasone furoate (MF) when administered alone via MF Twisthaler® (TH) or as an indacaterol acetate/MF fixed…
- Trial name
- NCT04589663
- Testing
- Mometasone furoate, QMF149, Standard of Care (Soc)
- Where
- 3 sites in Hungary, South Africa
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Multiple-dose Pharmacokinetics Study of "SYN006 HFA MDI" Administered Orally to Healthy Volunteers
Budesonide + Procaterol HFA MDI is a novel asthma product containing both budesonide and procaterol in a single inhaler. Budesonide is a corticosteroid that treats underlying airway inflammation in asthma.
- Trial name
- NCT02165033
- Testing
- Budesonide/Procaterol 180/10 X 4 puffs
- Where
- Taiwan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Intech Biopharm Ltd.
Asthma
A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects
To determine the safety and tolerability of Arformoterol Tartrate in children with asthma
- Trial name
- NCT00583947
- Testing
- arformoterol, levalbuterol
- Where
- 14 sites in United States
- Volunteers
- 53 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma
Efficacy and tolerability of the fixed combination Beclomethasone Dipropionate /Formoterol in patients with mild to moderate persistent asthma.
- Trial name
- NCT00862264
- Testing
- Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
- Volunteers
- 286 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma Bronchiale, Bronchiectasis
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with airway mucus hypersecretion in chronic airway inflammatory diseases
- Conditions
- Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06820749
- Testing
- HSK31858
- Where
- China
- Volunteers
- 309 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma
This study is a randomized, double-Blind, placebo-controlled, Single and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in…
- Trial name
- NCT07436949
- Testing
- BBT002
- Where
- 12 sites in China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
Allergic Rhinitis, Rhinoconjunctivitis
Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma
Safety study of Depigoid vaccine Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), to treat allergic rhinitis or rhinoconjunctivitis with or without asthma.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Mild Persistent Asthma, Mild Intermittent Asthma
- Trial name
- NCT01591343
- Testing
- Depigoid® (500 DPP/ml)
- Where
- 10 sites in Spain
- Volunteers
- 8 people
- Sponsor
- Laboratorios Leti, S.L.
Chronic Rhinosinusitis With Nasal Polyps, Asthma
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving chronic…
- Trial name
- EVEREST (NCT04998604)
- Testing
- Dupilumab, Omalizumab
- Where
- 87 sites in United States, Belgium and 15 more
- Volunteers
- 360 people
- Sponsor
- Sanofi
Asthma
Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination product and its components on protection from…
- Trial name
- NCT01128595
- Testing
- FF/GW642444M, GW642444M, Fluticasone Furoate
- Where
- 4 sites in Australia, New Zealand and 1 more
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence
The goal of this observational study is to determine if using the SiA® (Systematic Intervention Agent) system can improve inhaler technique and medication adherence in adults with asthma who are already using Trimbow pMDI…
- Trial name
- SiASMARTer (NCT06908421)
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Chiesi Pharma AB, Nordic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.